Member access

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Actelion Ltd    ATLN   CH0010532478

ACTELION LTD (ATLN)

28
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Actelion Ltd
Develops, produces and markets pharmaceutical drugs

Actelion Ltd. is a biopharmaceutical company, which engages in the development and commercialization of drugs.

The company discovers, develops and commercializes innovative low molecular weight drugs for high unmet medical needs.

Its products are used for human therapeutics for life threatening diseases such as cardiovascular, cardiopulmonary, immunological, metabolic, and nervous system disorders.

The company was founded by by Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Mueller, and Thomas Widmann on December 17, 1997 and is headquartered in Allschwil, Switzerland.
Sales per Businesses
20122013Delta
CHF (in Million)%CHF (in Million)%
Drugs1,728100%1,786100% +3.21%
Sales per Regions
20122013Delta
CHF (in Million)%CHF (in Million)%
United States709.6541.1%767.9643% +7.59%
Europe616.9635.7%632.0635.4% +2.39%
Rest of the World368.8121.3%356.6620% -3.41%
Switzerland32.981.9%29.061.6% -13.52%
Managers
NameAgeSinceTitle
Jean-Paul Clozel, MD591997Chief Executive Officer & Director
Jean-Pierre Garnier PhD, MBA672011Chairman
Otto Schwarz, PhD592008Chief Operating Officer & Executive Vice President
André C. Muller, MBA502013Chief Financial Officer & Executive Vice President
Martine Clozel, MD591997Chief Scientific Officer & Senior Vice President
Michael Jacobi, PhD612009Director
Werner Henrich71-Director
Jean P. Malo CFA, MBA60-Director
Juhani Anttila60-Director
Carl B. Feldbaum702007Director
Shareholders
NameShares%
Actelion Ltd. 8,830,9027.34%
BlackRock Investment Management (UK) Ltd. 6,169,7635.13%
Rudolf Maag, MBA 6,067,3055.04%
Jean-Paul Clozel, MD 5,281,5444.39%
Orbis Investment Management Ltd. 3,568,4892.97%
Bellevue Asset Management AG 3,228,5452.68%
Fidelity Management & Research Co. 3,075,5402.56%
Wellington Management Co. LLP 2,601,4632.16%
Norges Bank Investment Management 2,310,0201.92%
State Street Global Advisors Ltd. 1,556,2001.29%
Holdings
NameShares%Valuation
Actelion Ltd (ATLN) 8,830,9027.34%1,117,306,209 USD
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Advertisement
Surperformance© rating
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
PER
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
More Ratings
Sector Biotechnology & Medical Research
Growth (Revenue) Profitability
ITI INC
ACTELION LTD
SHANGHAI RAAS BLO..
-
MEDIVATION INC
INTERCEPT PHARMAC..
MANNKIND CORPORAT..
BEIJING SL PHARMA..
NPS PHARMACEUTICA..
HUALAN BIOLOGICAL..
GENMAB A/S
TONGHUA DONGBAO P..
MEDIGEN BIOTECHNO..
-
GW PHARMACEUTICAL..
BIOCON LTD
KERYX BIOPHARMACE..
OPHTHOTECH CORP
AGIOS PHARMACEUTI..
CLOVIS ONCOLOGY I..
ACORDA THERAPEUTI..
DYAX CORP.
Sector Biotechnology & Medical Research
Company contact information
16 Gewerbestrasse
CH-4123 Allschwil
Switzerland

Phone : +41 61 565 65 65
Fax : +41 61 565 65 00
Internet : http://www.actelion.com
Markets and indexes
- SIX Swiss Exchange
- Main Standard
- SMI /
Stock Exchange Codes
- ISIN Code :  CH0010532478
- Bloomberg Code :  ATLN:VX
- Reuters Code :  ATLN.VX
- Datastream Code :  S:ATLN
© 2014 Factset    © 2014 Cofisem   
Dynamic quotes  
ON
| OFF